Table 1 Demographic and clinical characteristics of study population and comparisons between subgroups
Variables | Total | Low baPWV Group | High baPWV Group | p Value |
|---|---|---|---|---|
(n=96) | (n=56) | (n=40) | ||
Female Gender | 50.0% | 37.5% | 67.5% | 0.004 |
Age (years) | 63.92 ± 14.24 | 58.34 ± 14.13 | 71.73 ± 10.26 | <0.001 |
CCI (score) | 5.0 (2.0, 9.0) | 4.0 (2.0, 8.0) | 5.0 (3.0, 9.0) | 0.054 |
PD duration (Months) | 44.47 ± 27.89 | 40.86 ± 26.12 | 49.53 ± 29.80 | 0.134 |
SBP (mmHg) | 135.75 ± 20.13 | 137.07 ± 20.58 | 133.90 ± 19.59 | 0.450 |
DBP (mmHg) | 76.21 ± 14.58 | 78.39 ± 13.32 | 73.15 ± 15.84 | 0.082 |
MAP (mmHg) | 96.06 ± 14.81 | 97.95 ± 13.95 | 93.40 ± 15.73 | 0.138 |
PP (mmHg) | 59.54 ± 16.07 | 58.68 ± 17.08 | 60.75 ± 14.68 | 0.536 |
BMI (kg/m2) | 23.44 ± 3.65 | 23.26 ± 3.47 | 23.70 ± 3.92 | 0.559 |
Dose of EPO (U/kg.week) | 136.95 ± 98.18 | 137.35 ± 90.53 | 136.39 ± 109.18 | 0.963 |
RAS inhibitor use | 62.5% | 67.9% | 55.0% | 0.200 |
β-Blocker use | 13.5% | 14.3% | 12.5% | 0.801 |
Hyperlipidemia | 40.6% | 39.3% | 42.5% | 0.752 |
Previous CVD history | 26.0% | 16.1% | 40.0% | 0.008 |
APD use | 33.3% | 41.1% | 22.5% | 0.057 |
Low-GDP PDF use | 36.5% | 33.9% | 40.0% | 0.542 |
Diabetes mellitus | 34.4% | 32.1% | 37.5% | 0.586 |
baPWV (m/s) | 21.20 ± 5.63 | 17.49 ± 2.41 | 26.39 ± 4.66 | <0.001 |